Trial · NCT02560012
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
NCT02560012, Phase 2, Terminated, The University of Texas Health Science Center, Houston; results first posted 2018-10-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Personalized Targeted Inhibitors Treatment in Renal Cell Cancer. Trials, record NCT02560012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02560012
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- NCT number
- NCT02560012
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sunitinib, Temsirolimus, Sorafenib, Pazopanib, Everolimus, Axitinib
- First posted
- 2015-09-25
- Last updated
- 2018-10-12
- Results first posted
- 2018-10-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Progressed | From date of enrollment until the date of first documented progression, date of death from any cause, or date that the study was stopped, whichever came first, an average of 16 months | The PFS is defined as the time elapsed between treatment initiation and tumor progression or death from any cause, with censoring of patients who are lost to follow-up. Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): " At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Progressed | From date of enrollment until the date of first documented progression, date of death from any cause, or date that the study was stopped, whichever came first, an average of 16 months | All participants who received personalized therapy (sunitinib, temsirolimus, sorafenib, or pazopanib) based on their tumor's profile. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Progressed | Personalized Therapy | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Personalized Therapy | 3 | |
| Overall Study | COMPLETED | Personalized Therapy | 1 | |
| Overall Study | NOT COMPLETED | Personalized Therapy | 2 |
Source ClinicalTrials.gov
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Personalized Therapy | 1 | 3 | 1 |
| other | Anaphylaxis | Immune system disorders | Personalized Therapy | 1 | 3 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Personalized Therapy | 1 | 3 | 1 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Personalized Therapy | 2 | 3 | 2 |
| other | Bloating | Gastrointestinal disorders | Personalized Therapy | 1 | 3 | 2 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Personalized Therapy | 1 | 3 | 1 |
| other | Bronchial infection | Infections and infestations | Personalized Therapy | 1 | 3 | 1 |
| other | Bullous dermatitis | Skin and subcutaneous tissue disorders | Personalized Therapy | 1 | 3 | 1 |
| other | Constipation | Gastrointestinal disorders | Personalized Therapy | 1 | 3 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Personalized Therapy | 1 | 3 | 1 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Personalized Therapy | 0 | 3 |
| Total, other adverse events | Personalized Therapy | 3 | 3 |
| Total, serious adverse events | Personalized Therapy | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02560012
GET https://conductscience.org/api/trials/v1/NCT02560012/events?page=2